Epigenetics in bipolar disorder: a critical review of the literature.
Adult Survivors of Child Adverse Events
/ psychology
Affect
/ drug effects
Bipolar Disorder
/ drug therapy
DNA Methylation
Epidemiologic Research Design
Epigenesis, Genetic
Female
Gene-Environment Interaction
Genetic Association Studies
Histone Code
Humans
Male
Organ Specificity
Psychotropic Drugs
/ pharmacology
RNA, Untranslated
/ genetics
Journal
Psychiatric genetics
ISSN: 1473-5873
Titre abrégé: Psychiatr Genet
Pays: England
ID NLM: 9106748
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
pubmed:
9
12
2020
medline:
14
8
2021
entrez:
8
12
2020
Statut:
ppublish
Résumé
Bipolar disorder (BD) is a chronic, disabling disease characterised by alternate mood episodes, switching through depressive and manic/hypomanic phases. Mood stabilizers, in particular lithium salts, constitute the cornerstone of the treatment in the acute phase as well as for the prevention of recurrences. The pathophysiology of BD and the mechanisms of action of mood stabilizers remain largely unknown but several pieces of evidence point to gene x environment interactions. Epigenetics, defined as the regulation of gene expression without genetic changes, could be the molecular substrate of these interactions. In this literature review, we summarize the main epigenetic findings associated with BD and response to mood stabilizers. We searched PubMed, and Embase databases and classified the articles depending on the epigenetic mechanisms (DNA methylation, histone modifications and non-coding RNAs). We present the different epigenetic modifications associated with BD or with mood-stabilizers. The major reported mechanisms were DNA methylation, histone methylation and acetylation, and non-coding RNAs. Overall, the assessments are poorly harmonized and the results are more limited than in other psychiatric disorders (e.g. schizophrenia). However, the nature of BD and its treatment offer excellent opportunities for epigenetic research: clear impact of environmental factors, clinical variation between manic or depressive episodes resulting in possible identification of state and traits biomarkers, documented impact of mood-stabilizers on the epigenome. Epigenetic is a growing and promising field in BD that may shed light on its pathophysiology or be useful as biomarkers of response to mood-stabilizer.
Identifiants
pubmed: 33290382
pii: 00041444-202102000-00001
doi: 10.1097/YPG.0000000000000267
doi:
Substances chimiques
Psychotropic Drugs
0
RNA, Untranslated
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-12Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Références
Abdolmaleky HM, Pajouhanfar S, Faghankhani M, Joghataei MT, Mostafavi A, Thiagalingam S. (2015). Antipsychotic drugs attenuate aberrant DNA methylation of DTNBP1 (Dysbindin) promoter in saliva and postmortem brain of patients with schizophrenia and psychotic bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 168:687–696.
Abdolmaleky HM, Cheng K-H, Faraone SV, Wilcox M, Glatt SJ, Gao F, et al. (2006). Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet. 15:3132–3145.
Abdolmaleky HM, Smith CL, Faraone SV, Shafa R, Stone W, Glatt SJ, Tsuang MT. (2004). Methylomics in psychiatry: modulation of gene-environment interactions may be through DNA methylation. Am J Med Genet B Neuropsychiatr Genet. 127B:51–59.
Abdolmaleky HM, Yaqubi S, Papageorgis P, Lambert AW, Ozturk S, Sivaraman V, Thiagalingam S. (2011). Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia and bipolar disorder. Schizophrenia Res. 129:183–190.
Abe N, Uchida S, Otsuki K, Hobara T, Yamagata H, Higuchi F, et al. (2011). Altered sirtuin deacetylase gene expression in patients with a mood disorder. J Psychiatr Res. 45:1106–1112.
Aberg KA, McClay JL, Nerella S, Clark S, Kumar G, Chen W, et al. (2014). Methylome-wide association study of schizophrenia: identifying blood biomarker signatures of environmental insults. JAMA Psychiatry. 71:255.
American Psychiatric Association. (2015). Manuel diagnostique et statistique des troubles mentaux version V. Arlington: ELSEVIER MASSON.
Arent CO, Valvassori SS, Fries GR, Stertz L, Ferreira CL, Lopes-Borges J, et al. (2011). Neuroanatomical profile of antimaniac effects of histone deacetylases inhibitors. Mol Neurobiol. 43:207–214.
Asai T, Bundo M, Sugawara H, Sunaga F, Ueda J, Tanaka G, et al. (2013). Effect of mood stabilizers on DNA methylation in human neuroblastoma cells. Int J Neuropsychopharmacol. 16:2285–2294.
Azevedo JA, Carter BS, Meng F, Turner DL, Dai M, Schatzberg AF, et al. (2016). The microRNA network is altered in anterior cingulate cortex of patients with unipolar and bipolar depression. J Psychiatr Res. 82:58–67.
Backlund L, Wei YB, Martinsson L, Melas PA, Liu JJ, Mu N, et al. (2015). Mood stabilizers and the influence on global leukocyte DNA methylation in bipolar disorder. Mol Neuropsychiatry. 1:76–81.
Banach E, Dmitrzak-Weglarz M, Pawlak J, Kapelski P, Szczepankiewicz A, Rajewska-Rager A, et al. (2017). Dysregulation of MiR-499, MiR-708 and MiR-1908 during a depression episode in bipolar disorders. Neurosci Lett. 654:117–119.
Banigan MG, Kao PF, Kozubek JA, Winslow AR, Medina J, Costa J, et al. (2013). Differential expression of exosomal microRNAs in prefrontal cortices of schizophrenia and bipolar disorder patients. PLoS ONE. 8: e48814.
Bannister AJ, Kouzarides T. (2011). Regulation of chromatin by histone modifications. Cell Res. 21:381–395.
Bavamian S, Mellios N, Lalonde J, Fass DM, Wang J, Sheridan SD, et al. (2015). Dysregulation of MiR-34a links neuronal development to genetic risk factors for bipolar disorder. Mol Psychiatry. 20:573–584.
Bengesser SA, Reininghaus EZ, Lackner N, Birner A, Fellendorf FT, Platzer M, et al. (2018). Is the molecular clock ticking differently in bipolar disorder? Methylation analysis of the clock gene ARNTL. World J Biol Psychiatry. 19 (sup2):S21–S29.
Berk M. (2009). Neuroprogression: pathways to progressive brain changes in bipolar disorder. Int J Neuropsychopharmacol. 12:441–445.
Burghardt KJ, Goodrich JM, Dolinoy DC, Ellingrod VL. (2015). DNA methylation, insulin resistance and second-generation antipsychotics in bipolar disorder. Epigenomics. 7:343–352.
Burghardt KJ, Khoury AS, Msallaty Z, Yi Z, Seyoum B. (2020). Antipsychotic medications and DNA methylation in schizophrenia and bipolar disorder: a systematic review. Pharmacotherapy. 40:331–342.
Carlberg L, Scheibelreiter J, Hassler MR, Schloegelhofer M, Schmoeger M, Ludwig B, et al. (2014). Brain-derived neurotrophic factor (BDNF)—epigenetic regulation in unipolar and bipolar affective disorder. J Affect Disord. 168:399–406.
Ceylan D, Scola G, Tunca Z, Isaacs-Trepanier C, Can G, Andreazza AC, et al. (2018). DNA redox modulations and global DNA methylation in bipolar disorder: effects of sex, smoking and illness state. Psychiatry Res. 261:589–596.
Chan RF, Shabalin AA, Montano C, Hannon E, Hultman CM, Fallin MD, et al. (2019). Independent methylome-wide association studies of schizophrenia detect consistent case–control differences. Schizophrenia Bull. 46:319–327.
Chaumette B, Kebir O, Dion PA, Rouleau GA, Krebs M-O. (2020). Reliability and correlation of mixture cell correction in methylomic and transcriptomic blood data. BMC Res Notes. 13:74.
Chaumette B, Kebir O, Krebs MO. (2017). [Genetics and epigenetics of schizophrenia and other psychoses]. Biologie Aujourd’hui. 211:69–82.
Chen C, Zhang C, Cheng L, Reilly JL, Bishop JR, Sweeney JA, et al. (2014). Correlation between DNA methylation and gene expression in the brains of patients with bipolar disorder and schizophrenia. Bipolar Disord. 16:790–799.
Chen Y, Sharma RP, Costa RH, Costa E, Grayson DR. (2002). On the epigenetic regulation of the human reelin promoter. Nucl Acids Res. 30:2930–2939.
Comes AL, Czamara D, Adorjan K, Anderson-Schmidt H, Andlauer TFM, Budde M, et al. (2020). The role of environmental stress and DNA methylation in the longitudinal course of bipolar disorder. Int J Bipolar Disord. 8:9.
Cruceanu C, Alda M, Nagy C, Freemantle E, Rouleau GA, Turecki G. (2013). H3K4 tri-methylation in synapsin genes leads to different expression patterns in bipolar disorder and major depression. Int J Neuropsychopharmacol. 16:289–299.
Cruceanu C, Kutsarova E, Chen ES, Checknita DR, Nagy C, Lopez JP, et al. (2016). DNA hypomethylation of synapsin II CpG islands associates with increased gene expression in bipolar disorder and major depression. BMC Psychiatry. 16:286.
Crump C, Sundquist K, Winkleby MA, Sundquist J. (2013). Comorbidities and mortality in bipolar disorder: A Swedish National Cohort Study. JAMA Psychiatry. 70:931.
D’Addario C, Dell’Osso B, Palazzo MC, Benatti B, Lietti L, Cattaneo E, et al. (2012). Selective DNA methylation of BDNF promoter in bipolar disorder: differences among patients with BDI and BDII. Neuropsychopharmacology. 37:1647–1655.
Dehghan A. (2018). Genome-wide association studies. Evangelou E (ed). In: Genetic Epidemiology. Methods in Molecular Biology. New York, NY: Springer New York. Vol. 1793: pp. 37–49.
Dell′Osso B, D′Addario C, Palazzo MC, Benatti B, Camuri G, Galimberti D, et al. (2014). Epigenetic modulation of BDNF gene: differences in DNA methylation between unipolar and bipolar patients. J Affect Disord. 166:330–333.
Dempster EL, Pidsley R, Schalkwyk LC, Owens S, Georgiades A, Kane F, et al. (2011). Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet. 20:4786–4796.
Detich N, Bovenzi V, Szyf M. (2003). Valproate induces replication-independent active DNA demethylation. J Biol Chem. 278:27586–27592.
Doi A, Park I-H, Wen B, Murakami P, Aryee MJ, Irizarry R, et al. (2009). Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet. 41:1350–1353.
Dong E, Ruzicka WB, Grayson DR, Guidotti A. (2015). DNA-methyltransferase1 (DNMT1) binding to CpG rich GABAergic and BDNF promoters is increased in the brain of schizophrenia and bipolar disorder patients. Schizophr Res. 167:35–41.
Edgar RD, Jones MJ, Meaney MJ, Turecki G, Kobor MS. (2017). BECon: a tool for interpreting DNA methylation findings from blood in the context of brain. Transl Psychiatry. 7:e1187.
Fiorentino A, O’Brien NL, Sharp SI, Curtis D, Bass NJ, McQuillin A. (2016). Genetic variation in the MiR-708 gene and its binding targets in bipolar disorder. Bipolar Disord. 18:650–656.
Fornaro M, De Berardis D, Anastasia A, Novello S, Fusco A, Cattaneo CI, et al. (2018). The identification of biomarkers predicting acute and maintenance lithium treatment response in bipolar disorder: a plea for further research attention. Psychiatry Res. 269:658–672.
Forstner AJ, Hofmann A, Maaser A, Sumer S, Khudayberdiev S, Mühleisen TW, et al. (2015). Genome-wide analysis implicates microRNAs and their target genes in the development of bipolar disorder. Transl Psychiatry. 5:e678.
Fries GR, Bauer IE, Scaini G, Wu M-J, Kazimi IF, Valvassori SS, et al. (2017). Accelerated epigenetic aging and mitochondrial DNA copy number in bipolar disorder. Transl Psychiatry. 7:1283.
Fries GR, Li Q, McAlpin B, Rein T, Walss-Bass C, Soares JC, Quevedo J. (2016). The role of DNA methylation in the pathophysiology and treatment of bipolar disorder. Neurosci Biobehav Rev. 68:474–488.
Gandal MJ, Zhang P, Hadjimichael E, Walker RL, Chen C, Liu S, et al. (2018). Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science. 362:eaat8127.
Gavin DP, Kartan S, Chase K, Jayaraman S, Sharma RP. (2009a). Histone deacetylase inhibitors and candidate gene expression: an in vivo and in vitro approach to studying chromatin remodeling in a clinical population. J Psychiatr Res. 43:870–876.
Geschwind DH, Flint J. (2015). Genetics and genomics of psychiatric disease. Science (New York, N.Y.). 349:1489–1494.
Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes TRH, Cipriani A, et al. (2016). Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol (Oxford, England). 30:495–553.
Gordovez FJA, McMahon FJ. (2020). The genetics of bipolar disorder. Mol Psychiatry. 25:544–559.
Goud A, Bruno Etain C, Bellivier F, Marie-Claire C. (2018). DNA methylation as a biomarker of treatment response variability in serious mental illnesses: a systematic review focused on bipolar disorder, schizophrenia, and major depressive disorder. Int J Mol Sci. 19:3026.
Grof P, Alda M, Gror E, Zvolsky P, Walsh M. (1994). Lithium response and genetics of affective disorders. J Affect Disord. 32:85–95.
Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M, et al. (2002). Is response to prophylactic lithium a familial trait? J Clin Psychiatry. 63:942–947.
Guella I, Sequeira A, Rollins B, Morgan L, Torri F, van Erp TGM, et al. (2013). Analysis of MiR-137 expression and Rs1625579 in dorsolateral prefrontal cortex. J Psychiatr Res. 47:1215–1221.
Gürel C, Ceren Kuşçu G, Yavaşoğlu A, Avci Ç. (2020). The clues in solving the mystery of major psychosis: the epigenetic basis of schizophrenia and bipolar disorder. Neurosci Biobehav Rev. 113:51–61.
Ha M, Narry Kim V. (2014). Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 15:509–524.
Hirschfeld RMA. (2004). Bipolar depression: the real challenge. Eur Neuropsychopharmacol. 14 (Suppl 2):S83–S88.
Hobara T, Uchida S, Otsuki K, Matsubara T, Funato H, Matsuo K, et al. (2010). Altered gene expression of histone deacetylases in mood disorder patients. J Psychiatr Res. 44:263–270.
Horvath S. (2013). DNA methylation age of human tissues and cell types. Genome Biol. 14:R115.
Houtepen LC, van Bergen AH, Vinkers CH, Boks MPM. (2016). DNA methylation signatures of mood stabilizers and antipsychotics in bipolar disorder. Epigenomics. 8:197–208.
Hui TP, Kandola A, Shen L, Lewis G, Osborn DPJ, Geddes JR, Hayes JF. (2019). A systematic review and meta-analysis of clinical predictors of lithium response in bipolar disorder. Acta Psychiatr Scand. 140:94–115.
Jenkins TG, Aston KI, Pflueger C, Cairns BR, Carrell DT. (2014). Age-associated sperm DNA methylation alterations: possible implications in offspring disease susceptibility. PLoS Genet. 10: e1004458.
Jin XF, Wu N, Wang L, Li J. (2013). Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases. Cell Mol Neurobiol. 33:601–613.
Kaminsky Z, Tochigi M, Jia P, Pal M, Mill J, Kwan A, et al. (2012). A multi-tissue analysis identifies HLA complex group 9 gene methylation differences in bipolar disorder. Mol Psychiatry. 17:728–740.
Kandaswamy R, McQuillin A, Curtis D, Gurling H. (2014). Allelic association, DNA resequencing and copy number variation at the metabotropic glutamate receptor GRM7 gene locus in bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 165:365–372.
Kebir O, Chaumette B, Rivollier F, Miozzo F, Lemieux Perreault LP, Barhdadi A, et al. (2017). Methylomic changes during conversion to psychosis. Mol Psychiatry. 22:512–518.
Kim AH, Reimers M, Maher B, Williamson V, McMichael O, McClay JL, et al. (2010). MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders. Schizophrenia Res. 124:183–191.
Kimura R, Yoshizaki K, Osumi N. (2018). Risk of neurodevelopmental disease by paternal aging: a possible influence of epigenetic alteration in sperm. Kubota T, Fukuoka H (eds). In: Developmental Origins of Health and Disease (DOHaD). Advances in Experimental Medicine and Biology. Singapore: Springer Singapore. 1012: pp. 75–81.
Kleefstra T, Schenck A, Kramer JM, van Bokhoven H. (2014). The genetics of cognitive epigenetics. Neuropharmacology. 80:83–94.
Krzywinski M, Altman N. (2013). Power and sample size. Nat Methods. 10:1139–1140.
Kungulovski G, Jeltsch A. (2016). Epigenome editing: state of the art, concepts, and perspectives. Trends Genet. 32:101–113.
Kuratomi G, Iwamoto K, Bundo M, Kusumi I, Kato N, Iwata N, et al. (2008). Aberrant DNA methylation associated with bipolar disorder identified from discordant monozygotic twins. Mol Psychiatry. 13:429–441.
Latalova K, Kamaradova D, Prasko J. (2014). Suicide in bipolar disorder: a review. Psychiatria Danubina. 26:108–114.
Leavitt T, Hu MS, Longaker MT. (2017). Isolation of live fibroblasts by fluorescence-activated cell sorting. Rittié L (ed). In: Fibrosis. Methods in Molecular Biology. New York: Springer New York. Vol 1627. pp. 205–212.
Lester BM, Conradt E, Marsit C. (2016). Introduction to the special section on epigenetics. Child Dev. 87:29–37.
Li S, Zong L, Hou Y, Zhang W, Zhou L, Yang Q, et al. (2019). Altered DNA methylation of the AluY subfamily in schizophrenia and bipolar disorder. Epigenomics. 11:581–586.
Lockwood LE, Youssef NA. (2017). Systematic review of epigenetic effects of pharmacological agents for bipolar disorders. Brain Sci. 7:154.
Ludwig B, Dwivedi Y. (2016). Dissecting bipolar disorder complexity through epigenomic approach. Mol Psychiatry. 21:1490–1498.
Luykx G, Giuliani F, Giuliani G, Veldink J. (2019). Coding and non-coding RNA abnormalities in bipolar disorder. Genes. 10:946.
Maffioletti E, Cattaneo A, Rosso G, Maina G, Maj C, Gennarelli M, Tardito D, Bocchio-Chiavetto L. (2016). Peripheral whole blood microRNA alterations in major depression and bipolar disorder. J Affect Disord. 200:250–258.
Manchia M, Adli M, Akula N, Ardau R, Aubry J-M, Backlund L, et al. (2013). Woo. Edited by Kazutaka Ikeda. PLoS ONE. 8:e65636.
Milekic MH, Xin Y, O’Donnell A, Kumar KK, Bradley-Moore M, Malaspina D, et al. (2015). Age-related sperm DNA methylation changes are transmitted to offspring and associated with abnormal behavior and dysregulated gene expression. Mol Psychiatry. 20:995–1001.
Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, Bouchard L, et al. (2008). Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet. 82:696–711.
Miller BH, Zeier Z, Xi L, Lanz TA, Deng S, Strathmann J, et al. (2012). MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. Proc Natl Acad Sci U S A. 109:3125–3130.
Moreau MP, Bruse SE, David-Rus R, Buyske S, Brzustowicz LM. (2011). Altered microRNA expression profiles in postmortem brain samples from individuals with schizophrenia and bipolar disorder. Biol Psychiatry. 69:188–193.
National Collaborating Centre for Mental Health (UK). (2014). Bipolar disorder: the NICE guideline on the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. National Institute for Health and Care Excellence: Clinical Guidelines. London: The British Psychological Society and The Royal College of Psychiatrists.
Nohesara S, Ghadirivasfi M, Mostafavi S, Eskandari M-R, Ahmadkhaniha H, Thiagalingam S, Abdolmaleky HM. (2011). DNA hypomethylation of MB-COMT promoter in the DNA derived from saliva in schizophrenia and bipolar disorder. J Psychiatr Res. 45:1432–1438.
O’Connor RM, Gururajan A, Dinan TG, Kenny PG, Cryan JF. (2016). All roads lead to the MiRNome: MiRNAs have a central role in the molecular pathophysiology of psychiatric disorders. Trends Pharmacol Sci. 37:1029–1044.
Perroud N, Zewdie S, Stenz L, Adouan W, Bavamian S, Prada P, et al. (2016). Methylation of Serotonin receptor 3A in ADHD, borderline personality, and bipolar disorders: link with severity of the disorders and childhood maltreatment: research article: epigenetics of 5 HT3A R in psychiatric disorders. Depression Anxiety. 33:45–55.
Peschansky VJ, Wahlestedt C. (2014). Non-coding RNAs as direct and indirect modulators of epigenetic regulation. Epigenetics. 9:3–12.
Pulay AJ, Réthelyi JM. (2016). Multimarker analysis suggests the involvement of BDNF signaling and microRNA biosynthesis in suicidal behavior. Am J Med Genet B Neuropsychiatr Genet. 171:763–776.
Rao JS, Keleshian VL, Klein S, Rapoport SI. (2012). Epigenetic modifications in frontal cortex from Alzheimer’s disease and bipolar disorder patients. Transl Psychiatry. 2:e132.
Roberts S, Suderman M, Zammit S, Watkins SH, Hannon E, Mill J, et al. (2019). Longitudinal investigation of DNA methylation changes preceding adolescent psychotic experiences. Transl Psychiatry. 9:69.
Rong H, Liu TB, Yang KJ, Yang HC, Wu DH, Liao CP, et al. (2011). MicroRNA-134 plasma levels before and after treatment for bipolar mania. J Psychiatr Res. 45:92–5.
Sabunciyan S, Maher B, Bahn S, Dickerson F, Yolken RH. (2015). Association of DNA methylation with acute mania and inflammatory markers. Transl Psychiatry. 9:e0132001.
Schizophrenia Working Group of the Psychiatric Genomics Consortium. (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature. 511:421–427.
Sharma RP, Rosen C, Kartan S, Guidotti A, Costa E, Grayson DR, Chase K. (2006). Valproic acid and chromatin remodeling in schizophrenia and bipolar disorder: preliminary results from a clinical population. Schizophrenia Res. 88:227–231.
Smalheiser NR, Lugli G, Zhang H, Rizavi H, Cook EH, Dwivedi Y. (2014). Expression of microRNAs and other small RNAs in prefrontal cortex in schizophrenia, bipolar disorder and depressed subjects. PLoS ONE. 9:e86469.
Smoller JW, Finn CT. (2003). Family, twin, and adoption studies of bipolar disorder. Am J Med Genet C Semin Med Genet. 123C:48–58.
Strazisar M, Cammaerts S, van der Ven K, Forero DA, Lenaerts A-S, Nordin A, et al. (2015). MIR137 variants identified in psychiatric patients affect synaptogenesis and neuronal transmission gene sets. Mol Psychiatry. 20:472–481.
Sugawara H, Iwamoto K, Bundo M, Ueda J, Miyauchi T, Komori A, et al. (2011). Hypermethylation of serotonin transporter gene in bipolar disorder detected by epigenome analysis of discordant monozygotic twins. Transl Psychiatry. 1:e24.
Sugawara H, Murata Y, Ikegame T, Sawamura R, Shimanaga S, Takeoka Y, et al. (2018). DNA methylation analyses of the candidate genes identified by a methylome-wide association study revealed common epigenetic alterations in schizophrenia and bipolar disorder: epigenetic alterations in SZ and BD. Psychiatry Clin Neurosci. 72:245–254.
Suzuki MM, Bird A. (2008). DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet. 9:465–476.
Tabor HK, Risch NJ, Myers RM. (2002). Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genet. 3:391–397.
Teroganova N, Girshkin L, Suter CM, Green MJ. (2016). DNA methylation in peripheral tissue of schizophrenia and bipolar disorder: a systematic review. BMC Genet. 17:27.
Tondo L, Hennen J, Baldessarini RJ. (2001). Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand. 104:163–172.
Veldic M, Kadriu B, Maloku E, Agis-Balboa RC, Guidotti A, Davis JM, Costa E. (2007). Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. Schizophrenia Res. 91:51–61.
Walker RM, Christoforou AN, McCartney DL, Morris SW, Kennedy NA, Morten P, et al. (2016). DNA methylation in a Scottish family multiply affected by bipolar disorder and major depressive disorder. Clin Epigenetics. 8:5.
Wei JW, Huang K, Yang C, Kang CS. (2017). Non-coding RNAs as regulators in epigenetics. Oncol Rep. 37:3–9.
Weigelt K, Bergink V, Burgerhout KM, Pescatori M, Wijkhuijs A, Drexhage HA. (2013). Down-regulation of inflammation-protective microRNAs 146a and 212 in monocytes of patients with postpartum psychosis. Brain Behav Immun. 29:147–155.
Whalley HC, Papmeyer M, Romaniuk L, Sprooten E, Johnstone EC, Hall J, et al. (2012). Impact of a microRNA MIR137 susceptibility variant on brain function in people at high genetic risk of schizophrenia or bipolar disorder. Neuropsychopharmacology. 37:2720–2729.
Xiao Y, Camarillo C, Ping Y, Arana TB, Zhao H, Thompson PM, et al. (2014). The DNA methylome and transcriptome of different brain regions in schizophrenia and bipolar disorder. PLoS ONE. 9:e95875.
Xie T, Gorenjak V, Stathopoulou MG, Dadé S, Marouli E, Masson C, et al. (2019). Epigenome-Wide Association Study (EWAS) of blood lipids in healthy population from STANISLAS Family Study (SFS). Int J Mol Sci. 20:1014.
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders. 20:97–170.
Zhang X, Cozen AE, Liu Y, Chen Q, Lowe TM. (2016). Small RNA modifications: integral to function and disease. Trends Mol Med. 22:1025–1034.
Zhang Y, Liu Y, Liu H, Tang WH. (2019). Exosomes: biogenesis, biologic function and clinical potential. Cell Biosci. 9:19.
Zhou R, Yuan P, Wang Y, Hunsberger JG, Elkahloun A, Wei Y, et al. (2009). Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology. 34:1395–1405.